Biogen Pilot on Using Vocal Biomarkers to Identify Potential Trial Participants: From the DPHARM 2024 Archives
Biogen discussed pilots in which they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to identify potential patients and reduce the burden of pre-screening.
In this podcast from the DPHARM 2024 archives, Biogen discussed pilots in which they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to provide access to patients with a clinically validated cognitive assessment who might not otherwise have the foundation to start a conversation with their physician about their cognition, and to reduce the burden of pre-screening.
For more information, go to DPHARMconference.com.
Related Podcasts
View All
Are Site Networks the Solution to the Industry Productivity and Recruitment Challenge?
Biogen Pilot on Using Vocal Biomarkers to Identify Potential Trial Participants: From the DPHARM 2024 Archives
Accelerating Patient Enrollment in Clinical Trials by Deploying a Product Model Approach, from DPHARM 2024 Archives

